What is Zacks Research’s Estimate for MMSI Q4 Earnings?

Merit Medical Systems, Inc. (NASDAQ:MMSI) – Analysts at Zacks Research dropped their Q4 2024 earnings estimates for Merit Medical Systems in a report issued on Wednesday, November 20th. Zacks Research analyst I. Bandyopadhyay now expects that the medical instruments supplier will earn $0.81 per share for the quarter, down from their prior forecast of $0.83. The consensus estimate for Merit Medical Systems’ current full-year earnings is $3.36 per share. Zacks Research also issued estimates for Merit Medical Systems’ Q3 2026 earnings at $1.07 EPS.

Other equities analysts also recently issued research reports about the stock. Wells Fargo & Company raised their price objective on shares of Merit Medical Systems from $85.00 to $103.00 and gave the stock an “equal weight” rating in a report on Monday, September 16th. Piper Sandler reiterated an “overweight” rating and set a $110.00 price target (up previously from $100.00) on shares of Merit Medical Systems in a research note on Monday, September 9th. Robert W. Baird boosted their price objective on shares of Merit Medical Systems from $107.00 to $109.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. Bank of America raised their target price on Merit Medical Systems from $92.00 to $103.00 and gave the stock a “neutral” rating in a report on Monday, September 16th. Finally, Barrington Research reiterated an “outperform” rating and set a $114.00 target price on shares of Merit Medical Systems in a research report on Thursday, October 31st. Three analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $103.36.

Merit Medical Systems Stock Down 0.4 %

MMSI stock opened at $104.92 on Monday. The company has a market cap of $6.11 billion, a price-to-earnings ratio of 51.43, a P/E/G ratio of 2.62 and a beta of 0.89. The company has a debt-to-equity ratio of 0.57, a quick ratio of 3.82 and a current ratio of 5.36. The business’s 50-day moving average is $98.70 and its two-hundred day moving average is $91.16. Merit Medical Systems has a fifty-two week low of $65.46 and a fifty-two week high of $106.87.

Merit Medical Systems (NASDAQ:MMSI) last released its quarterly earnings results on Wednesday, October 30th. The medical instruments supplier reported $0.86 earnings per share for the quarter, beating the consensus estimate of $0.80 by $0.06. Merit Medical Systems had a return on equity of 15.61% and a net margin of 9.05%. The firm had revenue of $339.85 million for the quarter, compared to analysts’ expectations of $334.60 million. During the same period in the prior year, the firm earned $0.75 EPS. The company’s revenue was up 7.8% compared to the same quarter last year.

Insider Activity

In related news, Director F. Ann Millner sold 12,500 shares of the stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $101.55, for a total value of $1,269,375.00. Following the sale, the director now directly owns 32,391 shares of the company’s stock, valued at $3,289,306.05. This represents a 27.85 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Raul Jr. Parra sold 29,646 shares of the company’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $98.02, for a total value of $2,905,900.92. Following the completion of the transaction, the chief financial officer now directly owns 16,361 shares in the company, valued at $1,603,705.22. This trade represents a 64.44 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 3.70% of the company’s stock.

Hedge Funds Weigh In On Merit Medical Systems

A number of institutional investors have recently modified their holdings of the stock. Tidal Investments LLC increased its position in Merit Medical Systems by 1.0% during the 3rd quarter. Tidal Investments LLC now owns 10,398 shares of the medical instruments supplier’s stock valued at $1,028,000 after purchasing an additional 104 shares during the period. American Century Companies Inc. boosted its position in Merit Medical Systems by 2.9% during the second quarter. American Century Companies Inc. now owns 4,216 shares of the medical instruments supplier’s stock valued at $362,000 after purchasing an additional 118 shares in the last quarter. Xponance Inc. lifted its position in shares of Merit Medical Systems by 4.9% during the second quarter. Xponance Inc. now owns 3,621 shares of the medical instruments supplier’s stock valued at $311,000 after buying an additional 170 shares during the last quarter. Glenmede Trust Co. NA boosted its holdings in shares of Merit Medical Systems by 0.6% in the 3rd quarter. Glenmede Trust Co. NA now owns 28,637 shares of the medical instruments supplier’s stock valued at $2,830,000 after buying an additional 170 shares in the last quarter. Finally, Captrust Financial Advisors grew its position in shares of Merit Medical Systems by 2.6% in the 3rd quarter. Captrust Financial Advisors now owns 7,440 shares of the medical instruments supplier’s stock worth $735,000 after buying an additional 187 shares during the last quarter. 99.66% of the stock is owned by hedge funds and other institutional investors.

About Merit Medical Systems

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.